ClinicalTrials.gg

Program

denikitug

Its studies are mostly in Adenocarcinoma Of Esophagus · Colorectal Neoplasms, led by Gilead Sciences.

Furthest: phase 2, since Apr 7, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences33 open or runningphase 2since Apr 7, 2026Aug 11, 2021Dec 2028phase 2 · NCT07527858

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2021First study: phase 1 study in Advanced Solid TumorFirst studyNCT05007782 · 304 enrolled · United States, Australia, Canada and more
  2. Apr 7, 20262 phase 2 studiesPhase 2 reachedNCT07527858, NCT07546812

Ahead

  1. Dec 2028Primary completion: phase 2 study in Advanced Microsatellite Stable Colorectal CancerNCT07527858
  2. Dec 2028Primary completion: phase 1 study in Advanced Solid TumorNCT05007782
  3. Jan 2030Primary completion: phase 2 study in Adenocarcinoma Of EsophagusNCT07546812

TargetBeta

CCR8 →read by rule
“A humanized immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule

Other programs on CCR8

ProgramCompanyFurthest phaseStudies
cafelkibartSino Biopharmaceuticalphase 37
CCR8 Inhibitor IPG7236rulenanjing-immunophage-biotech-co-ltdphase 23
imzokitugBristol-Myers Squibbphase 22
Anti-CCR8 Antibody-drug Conjugate TAK-188ruleTakedaphase 21
Anti-CCR8 Monoclonal Antibody HC006rulehc-biopharma-incphase 12
azirkitugAbbViephase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07546812Adenocarcinoma Of Esophagus · United States, Australia, France and more2Active, not recruitingJan 2030120
NCT07527858Advanced Microsatellite Stable Colorectal Cancer · United States, Australia, South Korea and more2RecruitingDec 2028170
NCT05007782Advanced Solid Tumor · United States, Australia, Canada and more1Active, not recruitingDec 2028304

How it is read

Names in the registry

  • “Denikitug”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.